Suppr超能文献

诱导免疫抑制治疗后心脏移植首次心内膜心肌活检的时机——来自加拿大心脏移植中心的经验

Timing of the first endomyocardial biopsy in heart transplantation after induction immunosuppressive therapy--experience from Canadian Heart Transplant Centre.

作者信息

Málek F, Kaan A, Straatman L, Cheung A, Gnaszewski A

机构信息

Department of Internal Medicine I Faculty Hospital Kralovske Vinohrady, Third School of Medicine, Charles University, Prague, Czech Republic.

出版信息

Cas Lek Cesk. 2005;144(8):507-9; discussion 509.

Abstract

BACKGROUND

The exact time point at which the first endomyocardial biopsy could be safely performed after the heart transplantation has not been systematically studied. In an attempt to determine this time point in our population, the number and severity of acute rejection episodes in the first eight weeks after the heart transplantation were assessed in 91 patients who underwent the procedure at St Paul's Hospital, Vancouver between September 1996 and December 2002.

METHODS AND RESULTS

For the purpose of our analysis, acute rejection was defined as the grade > or =2 according the International Society for Heart and Lung Transplantation (ISHLT). Three hundred and sixty two endomyocardial biopsies were performed in 87 patients surviving to the first biopsy from one to eight weeks after the heart transplantation. In 85 patients who received induction immunosuppressive therapy, 13 episodes of acute rejection were identified. In two patients who did not receive the induction therapy, three episodes of acute rejection occurred. Acute rejection grade ISHLT 3 was found in 2 patients who did not receive induction therapy and in three patients who did. ISHLT grade 4 rejection occurred at weeks 5 and 7 in two patients who received induction therapy. Only one patient who received induction therapy had acute rejection within the first three weeks after the heart transplantation.

CONCLUSIONS

Our analysis reveals that the frequency of acute rejection within the first eight weeks after the heart transplantation using induction therapy is low in this cohort, suggesting that the first routine endomyocardial biopsy could be delayed until the week four post-transplant.

摘要

背景

心脏移植后首次安全进行心内膜心肌活检的确切时间点尚未得到系统研究。为了确定我们研究人群中的这个时间点,对1996年9月至2002年12月在温哥华圣保罗医院接受该手术的91例患者心脏移植后头八周内急性排斥反应的次数和严重程度进行了评估。

方法与结果

为了我们的分析目的,根据国际心肺移植学会(ISHLT)的标准,急性排斥反应定义为分级≥2级。在心脏移植后1至8周存活至首次活检的87例患者中进行了362次心内膜心肌活检。在接受诱导免疫抑制治疗的85例患者中,发现13次急性排斥反应发作。在未接受诱导治疗的2例患者中,发生了3次急性排斥反应发作。在未接受诱导治疗的2例患者和接受诱导治疗的3例患者中发现了ISHLT 3级急性排斥反应。在接受诱导治疗的2例患者中,ISHLT 4级排斥反应分别发生在第5周和第7周。只有1例接受诱导治疗的患者在心脏移植后的前三周内发生了急性排斥反应。

结论

我们的分析表明在该队列中使用诱导治疗的心脏移植后头八周内急性排斥反应的发生率较低,这表明首次常规心内膜心肌活检可以推迟到移植后第四周进行。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验